Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06891-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Kim M Pabst und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany. kim.pabst@uk-essen.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Gallium Radioisotopes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer Foundation, Universitätsklinikum Essen.
Abstract (Originalsprache)
Purpose
In metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [ 68 Ga]Ga-FAPI-46, 2-[ 18 F]FDG and [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007 PET. Material and Methods Patients with advanced, progressive mCRPC underwent clinical [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007, 2-[ 18 F]FDG and [ 68 Ga]Ga-FAPI-46 PET/CT to evaluate treatment with PSMA-directed RLT. Tumour detection/semiquantitative parameters were compared on a per-lesion/-region basis. Two phenotypes were defined: Criteria for the mixed phenotype were: (a) PSMA-negative findings for lymph node metastases ≥ 2.5 cm, any solid organ metastases ≥ 1.0 cm, or bone metastases with soft tissue component ≥ 1.0 cm, (b) low [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007 uptake and/or (c) balanced tumour uptake of all radioligands. The PSMA-dominant phenotype was assigned if the criteria were not met.
Results
In ten patients, 472 lesions were detected on all imaging modalities (miTNM regions: M1b: 327 (69.3%), M1a: 95 (20.1%), N1: 26 (5.5%), M1c: 18 (3.8%), T: 5 (1.1%) and Tr: 1 (0.2%). [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007 (n = 453 (96.0%)) demonstrates the highest detection rate, followed by [ 68 Ga]Ga-FAPI-46 (n = 268 (56.8%))/2-[ 18 F]FDG (n = 241 (51.1%)). Semiquantitative uptake was highest for [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007 (mean SUV max (interquartile range): 22.7 (22.5), vs. [ 68 Ga]Ga-FAPI-46 (7.7 (3.7)) and 2-[ 18 F]FDG (6.8 (4.7)). Seven/three patients were retrospectively assigned to the PSMA-dominant/mixed phenotype. Median overall survival was significantly longer for patients who underwent [ 177 Lu]Lu-PSMA-617 RLT and were retrospectively assigned to the PSMA-dominant phenotype (19.7 vs. 9.3 months).
Conclusion
Through whole-body imaging, we identify considerable inter- and intra-patient heterogeneity of mCRPC and potential imaging phenotypes. Regarding uptake and tumour detection, [ 68 Ga]Ga-/[ 18 F]F-PSMA-11/-1007 was superior to [ 68 Ga]Ga-FAPI-46 and 2-[ 18 F]FDG, while the latter two were comparable. Patients who underwent [ 177 Lu]Lu-PSMA-617 RLT based on clinical-decision making had a longer overall survival and could be assigned to the PSMA-dominant phenotype. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany. kim.pabst@uk-essen.de.
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. kim.pabst@uk-essen.de.
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
- Department of Urology, West German Cancer Center, University Hospital Essen, Essen, Germany.
ORCID-Profile: Kim M Pabst, Riccardo Mei
Förderung
- Prostate Cancer Foundation
- Universitätsklinikum Essen
Zitieren
APA
Pabst, K. M., Mei, R., Lückerath, K., Hadaschik, B. A., Kesch, C., Rawitzer, J., Kessler, L., Bodensieck, L. S., Hamacher, R., Pomykala, K. L., Fanti, S., Herrmann, K., & Fendler, W. P. (2024). Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06891-8
Vancouver
Pabst KM, Mei R, Lückerath K, Hadaschik BA, Kesch C, Rawitzer J, et al. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06891-8
BibTeX
@article{Pabst2024,
author = {Pabst, Kim M and Mei, Riccardo and Lückerath, Katharina and Hadaschik, Boris A and Kesch, Claudia and Rawitzer, Josefine and Kessler, Lukas and Bodensieck, Luisa S and Hamacher, Rainer and Pomykala, Kelsey L and Fanti, Stefano and Herrmann, Ken and Fendler, Wolfgang P},
title = {Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06891-8}
}
EUVIMED